is retatrutide glp 1 Triple Agonist (GLP-1/GIP/GCG) Understanding the Next-Gen Weight Loss
Description
The gradual dose escalation minimizes gastrointestinal adverse effects, which represent the most common side effects of the medication
But the biological plausibility is sound, and some clinicians are incorporating this strategy into their long-term GLP-1 treatment plans
[12] Sndergaard CS, et al
As you can see, most marketed biosimilars are excluded from the larger PBMs 2025 formularies
ZepBound, launched for obesity in late 2023, quickly added hundreds of millions in sales by mid-2025, its global sales were already in the hundreds of millions as clinics rolled out the new weight-loss injection
